Ascendis Pharma A/S $ASND Shares Newly Purchased by Avior Wealth Management LLC

Key Points

• Avior Wealth Management initiated a position in Ascendis Pharma, purchasing 5,236 shares valued at approximately $1.19 million during the third quarter. Several other institutional investors also increased or established holdings.
• Wall Street sentiment remains positive, with a consensus “Buy” rating and an average price target of $309.26, despite Barclays lowering its target to $329.
• Ascendis Pharma shares opened at $227, while the company’s latest quarterly results showed revenue of $387.22 million but adjusted EPS of $1.03, below the $1.71 analyst consensus.

Avior Wealth Management LLC bought a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund bought 5,236 shares of the biotechnology company's stock, valued at approximately $1,193,000.

Several other institutional investors also recently modified their holdings of the stock. GAMMA Investing LLC boosted its stake in shares of Ascendis Pharma A/S by 52.5% in the 3rd quarter. GAMMA Investing LLC now owns 1,581 shares of the biotechnology company's stock valued at $360,000 after purchasing an additional 544 shares during the last quarter. Farther Finance Advisors LLC acquired a new position in Ascendis Pharma A/S in the third quarter valued at $139,000. Sapient Capital LLC boosted its position in Ascendis Pharma A/S by 3.9% during the third quarter. Sapient Capital LLC now owns 95,721 shares of the biotechnology company's stock valued at $21,808,000 after acquiring an additional 3,559 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in Ascendis Pharma A/S during the second quarter valued at $380,000. Finally, IFP Advisors Inc boosted its position in Ascendis Pharma A/S by 3,491.7% during the second quarter. IFP Advisors Inc now owns 431 shares of the biotechnology company's stock valued at $115,000 after acquiring an additional 419 shares during the last quarter.

Insider Buying and Selling

In other Ascendis Pharma A/S news, Director Jean-Jacques Bienaimé purchased 2,000 shares of Ascendis Pharma A/S stock in a transaction on Friday, August 14th. The shares were acquired at an average cost of $246.33 per share, for a total transaction of $492,660.00. Following the completion of the transaction, the director directly owned 2,900 shares of the company's stock, valued at approximately $714,357. The trade was a 222.22% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Mads Bodenhoff sold 3,000 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total transaction of $810,570.00. Following the transaction, the senior vice president owned 3,000 shares in the company, valued at $810,570. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 40.00% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on ASND shares. Barclays cut their price objective on shares of Ascendis Pharma A/S from $345.00 to $329.00 and set an "overweight" rating on the stock in a report on Friday, August 14th. Wall Street Zen upgraded shares of Ascendis Pharma A/S from a "hold" rating to a "buy" rating in a report on Saturday, October 10th. UBS Group set a $269.00 price target on shares of Ascendis Pharma A/S in a research report on Thursday. Weiss Ratings restated a "hold (c)" rating on shares of Ascendis Pharma A/S in a report on Tuesday. Finally, BMO Capital Markets restated an "outperform" rating on shares of Ascendis Pharma A/S in a report on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $309.26.

Ascendis Pharma A/S Trading Up 1.7%

Shares of ASND stock opened at $227.00 on Thursday. The company has a 50 day moving average of $245.52 and a 200-day moving average of $242.45. The company has a quick ratio of 2.32, a current ratio of 2.99 and a debt-to-equity ratio of 0.27. Ascendis Pharma A/S has a 12-month low of $186.05 and a 12-month high of $282.15. The firm has a market cap of $14.16 billion, a P/E ratio of 17.61 and a beta of 0.38.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing analysts' consensus estimates of $1.71 by ($0.68). The company had revenue of $387.22 million during the quarter, compared to the consensus estimate of $376.75 million. Ascendis Pharma A/S had a return on equity of 32.54% and a net margin of 70.99%. Sell-side analysts anticipate that Ascendis Pharma A/S will post 3.55 earnings per share for the current year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a biopharmaceutical company focused on developing therapies for rare diseases, particularly in endocrinology. The company uses its proprietary TransCon technology platform to design medicines intended to provide sustained release of therapeutic compounds and potentially improve treatment convenience and patient outcomes.

Ascendis Pharma's marketed products include Skytrofa (lonapegsomatropin-tcgb), a once-weekly growth hormone treatment for children with growth hormone deficiency, and Yorvipath (palopegteriparatide), a parathyroid hormone replacement therapy for adults with hypoparathyroidism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.